Cantargia AB (publ) announced the strengthening of its medical team. Roger Belusa has been appointed interim Chief Medical Officer (CMO), allowing his predecessor, Dr. Ignacio Garcia-Ribas, to take up a new position within Cantargia focusing on ongoing early phase clinical studies. Dr. Belusa has over 20 years of experience in various biotech and pharma companies developing cancer therapeutics.

The new appointment occurs as the clinical development of nadunolimab, Cantargia's most advanced program, rapidly advances towards the start of late-stage clinical studies in pancreatic cancer and non-small cell lung cancer. Several studies are also ongoing in parallel with the aim to broaden the development of nadunolimab. Belusa has a medical degree from Karolinska Institute where he also performed research studies in clinical pharmacology and oncology.

Belusa has a strong background in the field with over 20 years of experience in development of cancer therapeutics within companies such as Ipsen and Pfizer. He is also the founder of several medical start-ups with focus on bioinformatics, gene therapy and business development.